Insider Selling: Progyny, Inc. (NASDAQ:PGNY) Director Sells 6,618 Shares of Stock

Progyny, Inc. (NASDAQ:PGNY – Get Rating) Director Norman Payson sold 6,618 shares of the company’s stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $33.40, for a total value of $221,041.20. Following the completion of the transaction, the director now owns 424,648 shares in the company, valued at approximately $14,183,243.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Norman Payson also recently made the following trade(s):

• On Wednesday, July 6th, Norman Payson sold 6,618 shares of Progyny stock. The shares were sold at an average price of $29.38, for a total value of $194,436.84.
• On Wednesday, June 22nd, Norman Payson sold 6,618 shares of Progyny stock. The shares were sold at an average price of $27.35, for a total value of $181,002.30.
• On Wednesday, May 25th, Norman Payson sold 6,618 shares of Progyny stock. The shares were sold at an average price of $32.09, for a total value of $212,371.62.
• On Wednesday, May 11th, Norman Payson sold 6,618 shares of Progyny stock. The shares were sold at an average price of $33.45, for a total value of $221,372.10.

Progyny Stock Performance

NASDAQ:PGNY opened at $31.82 on Friday. The stock’s 50 day moving average price is $30.77 and its 200 day moving average price is $38.19. Progyny, Inc. has a 52 week low of $25.67 and a 52 week high of $68.32. The company has a market capitalization of $2.93 billion, a P/E ratio of 56.82, a P/E/G ratio of 8.58 and a beta of 1.96.

Progyny (NASDAQ:PGNY – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Progyny had a return on equity of 23.15% and a net margin of 10.09%. The firm had revenue of $172.22 million for the quarter, compared to the consensus estimate of $167.49 million. As a group, sell-side analysts forecast that Progyny, Inc. will post 0.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Progyny

Hedge funds have recently added to or reduced their stakes in the company. Schroder Investment Management Group increased its holdings in Progyny by 23.3% in the fourth quarter. Schroder Investment Management Group now owns 525,027 shares of the company’s stock worth $26,435,000 after buying an additional 99,236 shares during the last quarter. Hardy Reed LLC bought a new stake in Progyny during the first quarter worth approximately $117,000. Icapital Wealth LLC bought a new stake in Progyny during the fourth quarter worth approximately $378,000. Thrivent Financial for Lutherans boosted its position in Progyny by 50.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,076,182 shares of the company’s stock worth $54,186,000 after purchasing an additional 361,964 shares during the period. Finally, Nordea Investment Management AB boosted its position in Progyny by 9.6% during the first quarter. Nordea Investment Management AB now owns 282,415 shares of the company’s stock worth $14,451,000 after purchasing an additional 24,749 shares during the period. Institutional investors and hedge funds own 82.51% of the company’s stock.

Progyny Company Profile

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.